Skip to content

Long-term Follow-up Study of COVID-19

Long-term Large Sample Multicenter Follow-up Study of COVID-19

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05986435
Enrollment
5700
Registered
2023-08-14
Start date
2020-10-20
Completion date
2023-12-31
Last updated
2023-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

The goal of this observational study is to learn the long-term prognosis of patients and the clinical characteristics of complications, which is of great significance for treatment of novel coronavirus infection pneumonia. This trial plans to include 5700 inpatients with positive SARS CoV-2 nucleic acid test results. This trial does not involve the use of specific drug. Participants's health and psychological status will be observed at the preset time points. The blood, feces, urine samples of patients will be collected for relevant tests.

Detailed description

After the patients are enrolled, record the patient's treatment regimens, blood routine results, blood biochemistry results, cytokines results, lung imaging results, and cranial imaging results, understand the patient's current clinical manifestations, evaluate the patient's psychological status and quality of life, and collect samples of the patients' blood, feces, urine, and other related tests. Collection of clinical samples: collect blood, urine, throat swabs and other samples from patients with confirmed novel coronavirus pneumonia (Nucleic acid test positive), and collect samples for relevant tests at 3 months, 6 months, 12 months, 18 months, 24 months and 36 months after discharge of patients, and record the clinical manifestations of patients.

Interventions

None listed

Sponsors

Tongji Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with confirmed COVID-19

Exclusion criteria

* Combined infection with influenza virus, mycoplasma, and chlamydia.

Design outcomes

Primary

MeasureTime frame
clinical manifestation3 months, 6 months, 12 months, 18 months, 24 months, 36 months after patients discharge

Secondary

MeasureTime frame
cytokines level3 months, 6 months, 12 months, 18 months, 24 months, 36 months after patients discharge
psychological status3 months, 6 months, 12 months, 18 months, 24 months, 36 months after patients discharge
quality of life scores3 months, 6 months, 12 months, 18 months, 24 months, 36 months after patients discharge
cranial imaging results3 months, 6 months, 12 months, 18 months, 24 months, 36 months after patients discharge
lung imaging results3 months, 6 months, 12 months, 18 months, 24 months, 36 months after patients discharge
routine blood test results3 months, 6 months, 12 months, 18 months, 24 months, 36 months after patients discharge
treatment regimens3 months, 6 months, 12 months, 18 months, 24 months, 36 months after patients discharge
survival rate3 months, 6 months, 12 months, 18 months, 24 months, 36 months after patients discharge
blood biochemistry results3 months, 6 months, 12 months, 18 months, 24 months, 36 months after patients discharge

Countries

China

Contacts

Primary ContactQin Ning, Professor
qning@vip.sina.com+8613971521450

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026